Diabetes Education News

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and regulatory agencies such as the FDA a better understanding of how accurate their devices are.

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

High genetically predicted LDL was inversely associated with risk for incident diabetes, whereas the opposite trend was observed for CAD risk, researchers reported.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

Pregnant women with type 2 diabetes have a greater risk for perinatal mortality vs. pregnant women with type 1 diabetes, gestational diabetes and no diabetes, researchers reported in the American Journal of Obstetrics and Gynecology.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

In 2020 — the last year of the study period — researchers estimated that one in 10 new cases of type 2 diabetes mellitus could be connected to the intake of sugar-sweetened beverages.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation.

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker reported.